Study Evaluating IMA-638 in Asthma

Wyeth

Status and phase

Completed

Phase 1

Conditions

Asthma

Treatments

Drug: IMA-638

Study type

Interventional

Funder types

Industry

Identifiers

NCT00339872

3174K1-100

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Men and women of non-childbearing potential with mild to moderate asthma as defined by forced expiratory volume in 1 second (FEV1) greater than 70% predicted.
Well controlled asthma, as exhibited by completion of asthma questionnaire.
Otherwise healthy, except for asthma.